AB Science reports phase 1 data for AB8939 plus venetoclax in AML

June 29, 2026 1:59 AM

AB Science SA (Euronext: AB) reported results from Step 3 of its Phase 1 clinical trial evaluating the combination of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found